MindMed: Rethinking brain health with psychedelic therapy

What It Covers

MindMed CEO Rob Barrow outlines how the company is advancing LSD-based therapy through three Phase 3 pivotal trials targeting generalized anxiety disorder and major depressive disorder, with readouts expected in 2026 for a potential 50 million patient market.

Key Questions Answered

• •Indication scope strategy: Target broad populations rather than niche ones. MindMed pursues generalized anxiety disorder and major depressive disorder instead of treatment-resistant depression, expanding the addressable patient pool from a small fraction to tens of millions of patients across both conditions in the US alone.
• •Drug-only trial design: Study psychedelic compounds as standalone therapeutics, not in combination with psychotherapy. This removes a structural delivery bottleneck that would otherwise limit scalability and patient access post-approval, positioning MindMed to reach far larger populations than competitors using combination-therapy protocols.
• •Capital runway discipline: Secure funding through all pivotal data readouts, not just the next milestone. MindMed funded itself through 2027, covering three pivotal studies, while maintaining a lean 80-person team — a model that preserves flexibility during volatile biotech capital markets without sacrificing clinical execution.
• •Regulatory engagement timing: Build FDA relationships early, before pivotal data exists. MindMed's engagement since 2018, combined with a 2024 Breakthrough Therapy Designation, produced sustained senior-level FDA responsiveness — including prompt correspondence — even amid broader agency uncertainty, demonstrating that early partnership accelerates late-stage review confidence.